We have assumed that resources reported as required to treat hyperglycemia with ketosis in children at home and in NHS facilities, including a number of insulin pump set changes which may not be applicable, are generalizable to the BEGIN YOUNG 1 population.7 To remove the costs of pump set changes, however, could create bias, as costs associated with other components, such as test and ketone strips, could potentially be higher for non-pump users. The gene discussed is INS; the disease is Hyperglycemia.